Renovorx continues to grow intellectual property portfolio for its novel drug-delivery therapy platform

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing novel targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared delivery system, today highlighted its strong intellectual property (ip) position as it moves forward with commercial plans and clinical trial advancement in 2025, utilizing its novel trans-arterial micro-perfusion (tamp) therapy platform. earlier this year, renovorx publish.
RNXT Ratings Summary
RNXT Quant Ranking